


SUPPLEMENTAL MATERIALS

Supplemental Table 1. Change from baseline over 12 weeks for Global Assessment of Symptoms: “Overall, how would you rate your symptoms in the past 7 days?”


Symptom	Mean±SD	Placebo N=90	10 mg N=83	30 mg N=93	100 mg N=63
Overall Gastroparesis Symptoms	Baseline Score	2.3 ±0.8	2.3 ±0.7	2.3 ±0.7	2.4 ±0.7
	Week 12 score	1.4 ±0.7	1.2 ±0.9	1.3 ±0.8	1.2 ±0.8
	LS Mean Δ from Pbo		-0.29	-0.18	-0.28
	P-value		0.014	0.113	0.027
Nausea	Baseline Score	2.1 ±0.7	2.2 ±0.8	2.2 ±0.7	2.4 ±0.7
	Week 12 score	1.4 ±0.8	1.2 ±0.9	1.2 ±0.9	1.1 ±0.8
	LS Mean Δ from Pbo		-0.27	-0.24	-0.36
	P-value		0.038	0.062	0.012
Post-prandial Fullness	Baseline Score	2.9 ±0.9	3.0 ±1.0	3.0 ±0.8	2.9 ±0.9
	Week 12 score	2.3 ±0.9	2.0 ±0.9	1.9 ±0.9	2.0 ±0.9
	LS Mean Δ from Pbo		-0.34	-0.35	-0.23
	P-value		0.013	0.009	0.012
Bloating	Baseline Score	2.3 ±0.8	2.4 ±0.8	2.3 ±0.7	2.4 ±0.8
	Week 12 score	1.6 ±0.9	1.4 ±0.9	1.3 ±0.8	1.3 ±1.0
	LS Mean Δ from Pbo		-0.26	-0.24	-0.33
	P-value		0.051	0.054	0.022
Abdominal Pain	Baseline Score	2.0 ±0.8	2.1 ±0.9	1.9 ±0.8	2.0 ±0.9
	Week 12 score	1.2 ±0.8	1.1 ±0.9	1.1 ±0.9	0.9 ±0.9
	LS Mean Δ from Pbo		-0.18	-0.14	-0.33
	P-value		0.166	0.265	0.020

Supplemental Figure 1. Improvements in GCSI-DD at week 12 (p comparisons vs. placebo)



Data mean + SEM; P comparison with placebo

Supplemental Figure 2. Percent decrease in gastric emptying $T_{1/2}$ at end of treatment period compared to baseline in each group.



Data mean + SEM